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Abstract
β-(1,3)/(1,6) D-glucan, a component of the fungal cell wall, has been shown to stimulate the immune
system, enhance hematopoiesis, amplify killing of opsonized tumor cells and increase neutrophil
chemotaxis and adhesion. In view of these attributes, the β-glucans should be studied for both their
therapeutic efficacy in patients with cancer as well as an adjunctive therapy in patients receiving
chemotherapy as a maneuver to limit suppression of hematopoiesis.
In this study, twenty patients with advanced malignancies receiving chemotherapy were given a β-
(1,3)/(1,6) D-glucan preparation (MacroForce plus IP6, ImmuDyne, Inc.) and monitored for
tolerability and effect on hematopoiesis. Our results lead us to conclude that β-glucan is well-
tolerated in cancer patients receiving chemotherapy, may have a beneficial effect on hematopoiesis
in these patients and should be studied further, especially in patients with chronic lymphocytic
leukemia and lymphoma.
Background
β-(1,3)/(1,6) D-glucan is a long chain polymer of glucose
from the fungal cell wall which has been shown to have a
number of immunomodulatory properties as well as
effects on hematopoiesis and as a radiation protectant.
It has been well-demonstrated that the β-glucans increase
neutrophil chemotaxis and adhesion, synergize with mye-
loid growth factors to enhance hematopoiesis and mobi-
lize peripheral blood progenitor cells in vivo, directly
stimulate committed myeloid progenitor cells and
improve survival and hematopoietic regeneration in irra-
diated mice [1-7].
Furthermore, the β-glucans have been shown to amplify
the phagocytic killing of opsonized tumor cells and com-
bine with monoclonal antibodies to increase their tumor-
icidal activity [8].
Based on these properties, this study was designed to test
the safety of an adjunctive treatment with β-(1,3)/(1,6) D-
glucan in patients with advanced malignancies receiving
chemotherapy. In addition, because the β-glucans have
been shown to improve hematopoiesis in animals and
because chemotherapy generally induces cytopenias in
humans, we also sought to determine if the β-glucan
administered in this study exerted an effect on blood
counts in patients with advanced malignancies receiving
chemotherapy compared with pretreatment blood counts
in patients receiving chemotherapy alone.
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Methods
Twenty patients with advanced malignancies receiving
chemotherapy received the β-(1,3)/(1,6) D-glucan prepa-
ration, MacroForce plus IP6 (ImmuDyne, Mount Kisco,
NY), one tablet twice a day by mouth after granting
informed consent. This study was approved by the ethics
committee of the University Medical Group. All patients
had received at least one course of chemotherapy prior to
entering the study, were between 38 and 84 years old and
had a performance status of 0 to 2, according to the crite-
ria of the World Health Organization.
Patients were monitored every two weeks for side effects
and complete blood counts were obtained monthly for six
months. Specifically, patients were asked to report any
new symptoms not experienced prior to initiation of the
study and to note if any prior chemotherapy-related
symptoms (e.g. nausea and vomiting) had changed after
the intiation of the study. If grade 3 or 4 hematologic tox-
icity developed, defined as an absolute neutrophil count
of less than 1000 uL or a platelet count of less than 50,000
uL, therapy would be withheld until the toxicity resolved.
After resolution, dosing would be reduced to one tablet by
mouth per day. Mean changes in blood counts during the
study were compared to the mean blood counts observed
prior to the initiation of the study.
The primary endpoint was to determine the tolerability of
the treatment and its effect on serial blood counts. Written
informed consent was obtained from each patient for
publication of this study.
Results
Table 1 demonstrates the characteristics of the patients
enrolled in this study. Table 2 notes the types of malig-
nancies experienced by these patients and the treatments
they were receiving.
None of the twenty patients reported any new symptoms
while taking the β-glucan. Sixty per cent of the patients
reported a sense of well-being while taking the β-glucan
and asked to remain on the treatment even after the com-
pletion of the study. Forty per cent of the patients who
experienced fatigue during their chemotherapy treatments
prior to entering the study reported feeling less fatigued
while taking the β-glucan. In addition, one patient with
lymphoma and significant cervical adenopathy who
delayed his standard chemotherapy for 4 weeks during the
study and only took the β-glucan, noted a marked reduc-
tion in the size of the nodes while taking the β-glucan
alone.
Table 3 shows the comparison of the mean blood counts
prior to entering the study with the mean blood counts
during the study. As can be seen, in general, there was a
trend to improved blood counts during the study as com-
pared with the pre-study period. There appeared to be
improvement especially of the white blood count during
the study period on this dose of β-glucan. Improvements
were also noted in the levels of hemoglobin and the plate-
let counts.
Discussion
The β-glucans are long-chain polymers of glucose in β-
(1,3)(1,6) linkages which comprise the fungal cell wall.
These glucans have been studied for their ability stimulate
hematopoiesis, protect against radiation injury and
amplify killing of opsonized tumor cells.
It has been shown that these glucans can increase neu-
trophil chemotaxis and adhesion in several in vivo and in
vitro  systems [1-3]. In addition, betafectin PGG-glucan
was able to synergize with myeloid growth factors in vivo
to enhance hematopoietic recovery and mobilize periph-
eral blood progenitor cells [4]. Treatment with glucans in
mice has been shown to increase survival and improve
hematopoietic regeneration after irradiation and that the
glucans act directly on commited myeloid progenitors to
improve hematopoiesis [5-7].
The effects of glucans on tumor cell killing has included
the observation that yeast β-glucan amplifies phagocytic
killing of iC3b-opsonized tumor cells, combine with
monoclonal antibodies to increase tumor cell death and
can increase macrophage cytotoxicity to tumor cells by
increasing nitrous oxide production [8-12].
Interestingly, toxicological assessment of a particulate
yeast (1,3)-β-D-glucan in rats revealed no adverse or toxic
effects on the animals [13,14].
The specific aim of this study was to determine the safety
and side effect profile of β-(1,3)/(1,6) D-glucan in
patients with advanced malignancies receiving chemo-
therapy and the effect of the glucan on hemtopoiesis in
these patients. Furthermore, because the β-glucans also
Table 1: Patient Characteristics
Characteristic Study Patients (N = 20)
Median age – yrs (range) 65 (38–84)
Sex (no.)
Male 10
Female 10
WHO Performance Score
01 4
15
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have immunomodulatory effects as noted above, we
monitored patients for any therapeutic effect of the glucan
even though this was an uncontrolled trial and this was
not a specific aim of the treatment paradigm.
This trial demonstrates that β-(1,3)/(1,6) D-glucan is
extremely well-tolerated in patients with advanced malig-
nancies receiving chemotherapy. No adverse effects or tox-
icities were reported by any of the patients when
compared to their symptom profile before entering the
study. On the contrary, a significant number of patients
reported a sense of well-being while taking the glucan, an
effect which should be studied further in a larger, control-
led trial.
There clearly was some amelioration of the blood counts
in patients taking the glucan as compared to the pretreat-
ment mean counts. This effect supports the data from ani-
Table 2: Patients' Diagnoses and Treatments
Patient # Diagnosis Treatment
1 non-small cell lung cancer carboplatin/taxol
2 pancreatic carcinoma VP-16/gemzar
3 breast carcinoma carboplatin/taxotere
4 breast carcinoma adriamycin/taxotere
5 non-small cell lung cancer carboplatin/taxol
6 non-small cell lung cancer carboplatin/taxol
7 small cell lung cancer VP-16/cisplatin
8 colon cancer 5 FU/leukovorin/oxaliplatin
9 breast cancer adriamycin/taxotere
10 breast cancer carboplatin/taxol
11 follicular lymphoma cytoxan/vincristine/prednisone
12 renal cell carcinoma cytoxan/nexavar
13 chondrosarcoma cytoxan/adriamycin/ifosphamide
14 colon cancer 5 FU/leukovorin/oxaliplatin
15 breast cancer adriamycin/taxotere
16 follicular lymphoma cytoxan/vincristine/prednisone
17 chronic lymphocytic leukemia alkeran/prednisone
18 chronic lymphocytic leukemia alkeran/prednisone
19 pancreatic carcinoma doxorubicin/gemzar
20 myelodysplastic syndrome hydroxyurea
Table 3: Change in Mean Complete Blood Count Values
Patient # White blood count (ul) Hemoglobin (gm/dl) Platelet count (ul)
1 + 100 +.03 +26,000
2 +1100 +.30 +23,000
3 +1700 +1.0 + 8,000
4 +1000 No change -23,000
5 No change No change No change
6 +1800 -0.2 +15,000
7 No change No change No change
8 + 600 +.60 No change
9 No change No change -4,000
10 + 300 +.30 No change
11 + 700 +.40 -21,000
12 No change No change No change
13 + 300 No change +33,000
14 No change No change No change
15 No change No change No change
16 + 600 +.70 + 3,000
17 + 200 +.20 No change
18 +100 No change No change
19 No change No change No change
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mal studies which demonstrates that the β-glucans
improve hematopoiesis through a variety of mechanisms.
This effect should also be studied in a larger, controlled
trial because if confirmed, the β-glucans could become an
important adjunctive treatment in patients receiving
chemotherapy to limit the cytopenias observed with these
therapies.
Lastly, because of the immunomodulatory properties of
the glucans, these agents may have direct tumoricidal
properties which deserve further investigation in a larger
population in a controlled setting. Our anecdotal experi-
ence in one patient with lymphoma and enlarged cervical
nodes who noted marked improvement on the β-glucan
alone is extremely interesting at the very least.
We conclude that β-(1,3)/(1,6) D-glucan can be safely
administered to patients with advanced malignancies
receiving chemotherapy and that this adjunctive therapy
may have beneficial effects on the blood counts in these
patients. Further studies are warranted in a larger patient
population to confirm this latter finding and to determine
if the β-glucans have tumoricidal effects in humans.
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